0

Close
 
Upcoming Allied Market Research
2023
Nocturnal Polyuria Treatment Market

Nocturnal Polyuria Treatment Market: Global Opportunity Analysis and Industry Forecast, 2023-2030 Market

LS : Pharmaceuticals
Report Code: A10542
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Nocturnal Polyuria Treatment Market

Request Now !

Nocturnal polyuria or nocturia is a condition that causes you to wake up during the night to urinate or increased frequency of having to urinate more often at night. It is important to distinguish nocturia (urinating too frequently) from polyuria (urinating too much volume). This condition becomes more common as people age and occurs in both men and women. It can be common for most people to wake up once during the night to urinate, but urinating more recurrently can be associated with daytime urinary frequency or the condition can occur by itself. Treatment of nocturia includes certain activities, such as restricting fluids and medications that reduce symptoms of overactive bladder

COVID-19 scenario analysis: 

Pharmaceutical and biotechnological companies together with governments around the globe are working to combat the COVID-19 outbreak, from supporting the development of vaccines to scheduling medicines supply chain challenges. Around 115 vaccine candidates and other 155 molecules are in the R&D pipeline. Furthermore, the commonly used drugs, such as hydroxychloroquine, have observed huge boost in demand for the management of COVID-19. In addition, increase has been experienced in the demand for COVID-19 management drugs, which is expected to offer potential opportunity for manufacturers of drugs, as many developed countries are short of these drugs. Owing to the growing demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is anticipated to witness a substantial growth in the next few years.

Top impacting factors: market scenario analysis, trends, drivers, and impact analysis

The major factor affecting the market include surge in geriatric population. In addition, increase in the prevalence of organ failure would help the market gain traction in the next few years. Furthermore, rise in cases of high salt intake and hypertension is expected to help the market gain momentum in the coming years. Improvement in the healthcare infrastructure in the current years and the development observed in the diagnostics segment would help the market flourish. However, COVID-19 impact may hinder the growth of the market.

Increase in the number of product launches 

Increase in the number of product launches would help the market flourish during the forecast period. For instance, in March 2017, the U.S. Food and Drug Administration approved Noctiva (desmopressin acetate) nasal spray for adults who are awaken at least two times per night to urinate due to a condition known as nocturnal polyuria (overproduction of urine during the night). In May 2018, Avadel Pharmaceuticals Plc. announced the launch of Noctiva (desmopressin acetate), an emulsified microdose Nasal Spray. Noctiva is the first and only FDA-approved treatment proven to help adults with nocturia due to nocturnal polyuria, a condition which causes the kidneys to overproduce urine at night. Noctiva safely and effectively treats a condition that causes more than 40 million Americans to wake two or more times per night to use the bathroom and prevents them from getting a good night’s sleep.

Surge in prevalence of nocturia 

Increase in prevalence of nocturia is anticipated to help the market boost in the coming years. According to the International Continence Society (ICS), around 45% of men aged 50–59 year, 60% of those aged 60–69 year, and around 75% in their seventies are affected. If a more restrictive definition of nocturia is considered (two or more voids per night), the figures drop to 10%, 20%, and 30%, respectively. Although the consensual ICS definition sticks to the cut-off of one void per night, many others argue that choosing two voids per night might be more clinically relevant and better correlated to quality of life (QoL) impairment.

Key benefits of the report:

  • This study presents the analytical depiction of the global nocturnal polyuria treatment industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global nocturnal polyuria treatment market share.
  • The current market is quantitatively analyzed to highlight the global nocturnal polyuria treatment market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market. 
  • The report provides a detailed global nocturnal polyuria treatment market analysis based on competitive intensity and how the competition will take shape in coming years. 

Questions answered in the nocturnal polyuria treatment market research report:

  • Which are the leading players active in the nocturnal polyuria treatment market?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What are the projections for the future that would help in tasking further strategic steps?

 Nocturnal Polyuria Treatment Market: Global Opportunity Analysis and Industry Forecast, 2020–2027 Report Highlights

Aspects Details
By Type
  • Antispasmodic
  • Desmopressin
  • Anticholinergic Drugs
  • Others
By Distribution Channel
  • Hospital Pharmacy
  • Online Pharmacy
  • Others
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players Glenmark Pharmaceuticals Limited,, Teva Pharmaceutical Industries Ltd,, Nexus Pharma Co., Ltd, Avadel Pharmaceuticals,, Vantia Therapeutics,, Urigen Pharmaceuticals, Inc.,, AA Pharma Inc.,, Astellas Pharma Inc.,, Ferring Holding SA,, Allergan, Inc.,
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: NOCTURNAL POLYURIA TREATMENT MARKET, BY TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Type

    • 4.2. Antispasmodic

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Desmopressin

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Anticholinergic Drugs

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Others

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

  • CHAPTER 5: NOCTURNAL POLYURIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Distribution Channel

    • 5.2. Hospital Pharmacy

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Online Pharmacy

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Others

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

  • CHAPTER 6: NOCTURNAL POLYURIA TREATMENT MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Type

      • 6.2.3. Market Size and Forecast, By Distribution Channel

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Nocturnal Polyuria Treatment Market

        • 6.2.5.1. Market Size and Forecast, By Type
        • 6.2.5.2. Market Size and Forecast, By Distribution Channel

      • 6.2.6. Canada Nocturnal Polyuria Treatment Market

        • 6.2.6.1. Market Size and Forecast, By Type
        • 6.2.6.2. Market Size and Forecast, By Distribution Channel

      • 6.2.7. Mexico Nocturnal Polyuria Treatment Market

        • 6.2.7.1. Market Size and Forecast, By Type
        • 6.2.7.2. Market Size and Forecast, By Distribution Channel

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Type

      • 6.3.3. Market Size and Forecast, By Distribution Channel

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Nocturnal Polyuria Treatment Market

        • 6.3.5.1. Market Size and Forecast, By Type
        • 6.3.5.2. Market Size and Forecast, By Distribution Channel

      • 6.3.6. Germany Nocturnal Polyuria Treatment Market

        • 6.3.6.1. Market Size and Forecast, By Type
        • 6.3.6.2. Market Size and Forecast, By Distribution Channel

      • 6.3.7. Italy Nocturnal Polyuria Treatment Market

        • 6.3.7.1. Market Size and Forecast, By Type
        • 6.3.7.2. Market Size and Forecast, By Distribution Channel

      • 6.3.8. Spain Nocturnal Polyuria Treatment Market

        • 6.3.8.1. Market Size and Forecast, By Type
        • 6.3.8.2. Market Size and Forecast, By Distribution Channel

      • 6.3.9. UK Nocturnal Polyuria Treatment Market

        • 6.3.9.1. Market Size and Forecast, By Type
        • 6.3.9.2. Market Size and Forecast, By Distribution Channel

      • 6.3.10. Russia Nocturnal Polyuria Treatment Market

        • 6.3.10.1. Market Size and Forecast, By Type
        • 6.3.10.2. Market Size and Forecast, By Distribution Channel

      • 6.3.11. Rest Of Europe Nocturnal Polyuria Treatment Market

        • 6.3.11.1. Market Size and Forecast, By Type
        • 6.3.11.2. Market Size and Forecast, By Distribution Channel

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Type

      • 6.4.3. Market Size and Forecast, By Distribution Channel

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Nocturnal Polyuria Treatment Market

        • 6.4.5.1. Market Size and Forecast, By Type
        • 6.4.5.2. Market Size and Forecast, By Distribution Channel

      • 6.4.6. Japan Nocturnal Polyuria Treatment Market

        • 6.4.6.1. Market Size and Forecast, By Type
        • 6.4.6.2. Market Size and Forecast, By Distribution Channel

      • 6.4.7. India Nocturnal Polyuria Treatment Market

        • 6.4.7.1. Market Size and Forecast, By Type
        • 6.4.7.2. Market Size and Forecast, By Distribution Channel

      • 6.4.8. South Korea Nocturnal Polyuria Treatment Market

        • 6.4.8.1. Market Size and Forecast, By Type
        • 6.4.8.2. Market Size and Forecast, By Distribution Channel

      • 6.4.9. Australia Nocturnal Polyuria Treatment Market

        • 6.4.9.1. Market Size and Forecast, By Type
        • 6.4.9.2. Market Size and Forecast, By Distribution Channel

      • 6.4.10. Thailand Nocturnal Polyuria Treatment Market

        • 6.4.10.1. Market Size and Forecast, By Type
        • 6.4.10.2. Market Size and Forecast, By Distribution Channel

      • 6.4.11. Malaysia Nocturnal Polyuria Treatment Market

        • 6.4.11.1. Market Size and Forecast, By Type
        • 6.4.11.2. Market Size and Forecast, By Distribution Channel

      • 6.4.12. Indonesia Nocturnal Polyuria Treatment Market

        • 6.4.12.1. Market Size and Forecast, By Type
        • 6.4.12.2. Market Size and Forecast, By Distribution Channel

      • 6.4.13. Rest of Asia Pacific Nocturnal Polyuria Treatment Market

        • 6.4.13.1. Market Size and Forecast, By Type
        • 6.4.13.2. Market Size and Forecast, By Distribution Channel

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Type

      • 6.5.3. Market Size and Forecast, By Distribution Channel

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Nocturnal Polyuria Treatment Market

        • 6.5.5.1. Market Size and Forecast, By Type
        • 6.5.5.2. Market Size and Forecast, By Distribution Channel

      • 6.5.6. South Africa Nocturnal Polyuria Treatment Market

        • 6.5.6.1. Market Size and Forecast, By Type
        • 6.5.6.2. Market Size and Forecast, By Distribution Channel

      • 6.5.7. Saudi Arabia Nocturnal Polyuria Treatment Market

        • 6.5.7.1. Market Size and Forecast, By Type
        • 6.5.7.2. Market Size and Forecast, By Distribution Channel

      • 6.5.8. UAE Nocturnal Polyuria Treatment Market

        • 6.5.8.1. Market Size and Forecast, By Type
        • 6.5.8.2. Market Size and Forecast, By Distribution Channel

      • 6.5.9. Argentina Nocturnal Polyuria Treatment Market

        • 6.5.9.1. Market Size and Forecast, By Type
        • 6.5.9.2. Market Size and Forecast, By Distribution Channel

      • 6.5.10. Rest of LAMEA Nocturnal Polyuria Treatment Market

        • 6.5.10.1. Market Size and Forecast, By Type
        • 6.5.10.2. Market Size and Forecast, By Distribution Channel

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning,2022

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. Teva Pharmaceutical Industries Ltd,

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Allergan, Inc.,

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Ferring Holding SA,

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Vantia Therapeutics,

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. Astellas Pharma Inc.,

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Urigen Pharmaceuticals, Inc.,

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. Glenmark Pharmaceuticals Limited,

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. AA Pharma Inc.,

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. Avadel Pharmaceuticals,

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. Nexus Pharma Co., Ltd

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL NOCTURNAL POLYURIA TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL NOCTURNAL POLYURIA TREATMENT MARKET FOR ANTISPASMODIC, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL NOCTURNAL POLYURIA TREATMENT MARKET FOR DESMOPRESSIN, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL NOCTURNAL POLYURIA TREATMENT MARKET FOR ANTICHOLINERGIC DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL NOCTURNAL POLYURIA TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL NOCTURNAL POLYURIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL NOCTURNAL POLYURIA TREATMENT MARKET FOR HOSPITAL PHARMACY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL NOCTURNAL POLYURIA TREATMENT MARKET FOR ONLINE PHARMACY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL NOCTURNAL POLYURIA TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL NOCTURNAL POLYURIA TREATMENT MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. NORTH AMERICA NOCTURNAL POLYURIA TREATMENT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. NORTH AMERICA NOCTURNAL POLYURIA TREATMENT, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 13. NORTH AMERICA NOCTURNAL POLYURIA TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 14. U.S. NOCTURNAL POLYURIA TREATMENT, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 15. U.S. NOCTURNAL POLYURIA TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 16. CANADA NOCTURNAL POLYURIA TREATMENT, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 17. CANADA NOCTURNAL POLYURIA TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 18. MEXICO NOCTURNAL POLYURIA TREATMENT, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 19. MEXICO NOCTURNAL POLYURIA TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 20. EUROPE NOCTURNAL POLYURIA TREATMENT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 21. EUROPE NOCTURNAL POLYURIA TREATMENT, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 22. EUROPE NOCTURNAL POLYURIA TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 23. FRANCE NOCTURNAL POLYURIA TREATMENT, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 24. FRANCE NOCTURNAL POLYURIA TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 25. GERMANY NOCTURNAL POLYURIA TREATMENT, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 26. GERMANY NOCTURNAL POLYURIA TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 27. ITALY NOCTURNAL POLYURIA TREATMENT, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 28. ITALY NOCTURNAL POLYURIA TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 29. SPAIN NOCTURNAL POLYURIA TREATMENT, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 30. SPAIN NOCTURNAL POLYURIA TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 31. UK NOCTURNAL POLYURIA TREATMENT, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 32. UK NOCTURNAL POLYURIA TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 33. RUSSIA NOCTURNAL POLYURIA TREATMENT, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 34. RUSSIA NOCTURNAL POLYURIA TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 35. REST OF EUROPE NOCTURNAL POLYURIA TREATMENT, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 36. REST OF EUROPE NOCTURNAL POLYURIA TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 37. ASIA-PACIFIC NOCTURNAL POLYURIA TREATMENT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 38. ASIA-PACIFIC NOCTURNAL POLYURIA TREATMENT, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 39. ASIA-PACIFIC NOCTURNAL POLYURIA TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 40. CHINA NOCTURNAL POLYURIA TREATMENT, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 41. CHINA NOCTURNAL POLYURIA TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 42. JAPAN NOCTURNAL POLYURIA TREATMENT, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 43. JAPAN NOCTURNAL POLYURIA TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 44. INDIA NOCTURNAL POLYURIA TREATMENT, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 45. INDIA NOCTURNAL POLYURIA TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 46. SOUTH KOREA NOCTURNAL POLYURIA TREATMENT, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 47. SOUTH KOREA NOCTURNAL POLYURIA TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 48. AUSTRALIA NOCTURNAL POLYURIA TREATMENT, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 49. AUSTRALIA NOCTURNAL POLYURIA TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 50. THAILAND NOCTURNAL POLYURIA TREATMENT, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 51. THAILAND NOCTURNAL POLYURIA TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 52. MALAYSIA NOCTURNAL POLYURIA TREATMENT, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 53. MALAYSIA NOCTURNAL POLYURIA TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 54. INDONESIA NOCTURNAL POLYURIA TREATMENT, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 55. INDONESIA NOCTURNAL POLYURIA TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 56. REST OF ASIA PACIFIC NOCTURNAL POLYURIA TREATMENT, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 57. REST OF ASIA PACIFIC NOCTURNAL POLYURIA TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 58. LAMEA NOCTURNAL POLYURIA TREATMENT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 59. LAMEA NOCTURNAL POLYURIA TREATMENT, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 60. LAMEA NOCTURNAL POLYURIA TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 61. BRAZIL NOCTURNAL POLYURIA TREATMENT, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 62. BRAZIL NOCTURNAL POLYURIA TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 63. SOUTH AFRICA NOCTURNAL POLYURIA TREATMENT, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 64. SOUTH AFRICA NOCTURNAL POLYURIA TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 65. SAUDI ARABIA NOCTURNAL POLYURIA TREATMENT, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 66. SAUDI ARABIA NOCTURNAL POLYURIA TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 67. UAE NOCTURNAL POLYURIA TREATMENT, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 68. UAE NOCTURNAL POLYURIA TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 69. ARGENTINA NOCTURNAL POLYURIA TREATMENT, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 70. ARGENTINA NOCTURNAL POLYURIA TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 71. REST OF LAMEA NOCTURNAL POLYURIA TREATMENT, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 72. REST OF LAMEA NOCTURNAL POLYURIA TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 73. TEVA PHARMACEUTICAL INDUSTRIES LTD,: KEY EXECUTIVES
  • TABLE 74. TEVA PHARMACEUTICAL INDUSTRIES LTD,: COMPANY SNAPSHOT
  • TABLE 75. TEVA PHARMACEUTICAL INDUSTRIES LTD,: OPERATING SEGMENTS
  • TABLE 76. TEVA PHARMACEUTICAL INDUSTRIES LTD,: PRODUCT PORTFOLIO
  • TABLE 77. TEVA PHARMACEUTICAL INDUSTRIES LTD,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 78. ALLERGAN, INC.,: KEY EXECUTIVES
  • TABLE 79. ALLERGAN, INC.,: COMPANY SNAPSHOT
  • TABLE 80. ALLERGAN, INC.,: OPERATING SEGMENTS
  • TABLE 81. ALLERGAN, INC.,: PRODUCT PORTFOLIO
  • TABLE 82. ALLERGAN, INC.,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 83. FERRING HOLDING SA,: KEY EXECUTIVES
  • TABLE 84. FERRING HOLDING SA,: COMPANY SNAPSHOT
  • TABLE 85. FERRING HOLDING SA,: OPERATING SEGMENTS
  • TABLE 86. FERRING HOLDING SA,: PRODUCT PORTFOLIO
  • TABLE 87. FERRING HOLDING SA,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 88. VANTIA THERAPEUTICS,: KEY EXECUTIVES
  • TABLE 89. VANTIA THERAPEUTICS,: COMPANY SNAPSHOT
  • TABLE 90. VANTIA THERAPEUTICS,: OPERATING SEGMENTS
  • TABLE 91. VANTIA THERAPEUTICS,: PRODUCT PORTFOLIO
  • TABLE 92. VANTIA THERAPEUTICS,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 93. ASTELLAS PHARMA INC.,: KEY EXECUTIVES
  • TABLE 94. ASTELLAS PHARMA INC.,: COMPANY SNAPSHOT
  • TABLE 95. ASTELLAS PHARMA INC.,: OPERATING SEGMENTS
  • TABLE 96. ASTELLAS PHARMA INC.,: PRODUCT PORTFOLIO
  • TABLE 97. ASTELLAS PHARMA INC.,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 98. URIGEN PHARMACEUTICALS, INC.,: KEY EXECUTIVES
  • TABLE 99. URIGEN PHARMACEUTICALS, INC.,: COMPANY SNAPSHOT
  • TABLE 100. URIGEN PHARMACEUTICALS, INC.,: OPERATING SEGMENTS
  • TABLE 101. URIGEN PHARMACEUTICALS, INC.,: PRODUCT PORTFOLIO
  • TABLE 102. URIGEN PHARMACEUTICALS, INC.,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 103. GLENMARK PHARMACEUTICALS LIMITED,: KEY EXECUTIVES
  • TABLE 104. GLENMARK PHARMACEUTICALS LIMITED,: COMPANY SNAPSHOT
  • TABLE 105. GLENMARK PHARMACEUTICALS LIMITED,: OPERATING SEGMENTS
  • TABLE 106. GLENMARK PHARMACEUTICALS LIMITED,: PRODUCT PORTFOLIO
  • TABLE 107. GLENMARK PHARMACEUTICALS LIMITED,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 108. AA PHARMA INC.,: KEY EXECUTIVES
  • TABLE 109. AA PHARMA INC.,: COMPANY SNAPSHOT
  • TABLE 110. AA PHARMA INC.,: OPERATING SEGMENTS
  • TABLE 111. AA PHARMA INC.,: PRODUCT PORTFOLIO
  • TABLE 112. AA PHARMA INC.,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 113. AVADEL PHARMACEUTICALS,: KEY EXECUTIVES
  • TABLE 114. AVADEL PHARMACEUTICALS,: COMPANY SNAPSHOT
  • TABLE 115. AVADEL PHARMACEUTICALS,: OPERATING SEGMENTS
  • TABLE 116. AVADEL PHARMACEUTICALS,: PRODUCT PORTFOLIO
  • TABLE 117. AVADEL PHARMACEUTICALS,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 118. NEXUS PHARMA CO., LTD: KEY EXECUTIVES
  • TABLE 119. NEXUS PHARMA CO., LTD: COMPANY SNAPSHOT
  • TABLE 120. NEXUS PHARMA CO., LTD: OPERATING SEGMENTS
  • TABLE 121. NEXUS PHARMA CO., LTD: PRODUCT PORTFOLIO
  • TABLE 122. NEXUS PHARMA CO., LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL NOCTURNAL POLYURIA TREATMENT MARKET SEGMENTATION
  • FIGURE 2. GLOBAL NOCTURNAL POLYURIA TREATMENT MARKET
  • FIGURE 3. SEGMENTATION NOCTURNAL POLYURIA TREATMENT MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN NOCTURNAL POLYURIA TREATMENT MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALNOCTURNAL POLYURIA TREATMENT MARKET
  • FIGURE 11. NOCTURNAL POLYURIA TREATMENT MARKET SEGMENTATION, BY BY TYPE
  • FIGURE 12. NOCTURNAL POLYURIA TREATMENT MARKET FOR ANTISPASMODIC, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. NOCTURNAL POLYURIA TREATMENT MARKET FOR DESMOPRESSIN, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. NOCTURNAL POLYURIA TREATMENT MARKET FOR ANTICHOLINERGIC DRUGS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. NOCTURNAL POLYURIA TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. NOCTURNAL POLYURIA TREATMENT MARKET SEGMENTATION, BY BY DISTRIBUTION CHANNEL
  • FIGURE 17. NOCTURNAL POLYURIA TREATMENT MARKET FOR HOSPITAL PHARMACY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. NOCTURNAL POLYURIA TREATMENT MARKET FOR ONLINE PHARMACY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. NOCTURNAL POLYURIA TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 21. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 22. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 23. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 24. COMPETITIVE DASHBOARD
  • FIGURE 25. COMPETITIVE HEATMAP: NOCTURNAL POLYURIA TREATMENT MARKET
  • FIGURE 26. Top player positioning, 2022
  • FIGURE 27. TEVA PHARMACEUTICAL INDUSTRIES LTD,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 28. TEVA PHARMACEUTICAL INDUSTRIES LTD,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 29. TEVA PHARMACEUTICAL INDUSTRIES LTD,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 30. ALLERGAN, INC.,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 31. ALLERGAN, INC.,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 32. ALLERGAN, INC.,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 33. FERRING HOLDING SA,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 34. FERRING HOLDING SA,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 35. FERRING HOLDING SA,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 36. VANTIA THERAPEUTICS,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 37. VANTIA THERAPEUTICS,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 38. VANTIA THERAPEUTICS,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 39. ASTELLAS PHARMA INC.,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 40. ASTELLAS PHARMA INC.,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 41. ASTELLAS PHARMA INC.,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 42. URIGEN PHARMACEUTICALS, INC.,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 43. URIGEN PHARMACEUTICALS, INC.,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 44. URIGEN PHARMACEUTICALS, INC.,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 45. GLENMARK PHARMACEUTICALS LIMITED,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 46. GLENMARK PHARMACEUTICALS LIMITED,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 47. GLENMARK PHARMACEUTICALS LIMITED,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 48. AA PHARMA INC.,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 49. AA PHARMA INC.,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 50. AA PHARMA INC.,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 51. AVADEL PHARMACEUTICALS,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 52. AVADEL PHARMACEUTICALS,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 53. AVADEL PHARMACEUTICALS,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 54. NEXUS PHARMA CO., LTD: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 55. NEXUS PHARMA CO., LTD: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 56. NEXUS PHARMA CO., LTD: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now
RELATED TAGS

Purchase Full Report of
Nocturnal Polyuria Treatment Market

Start reading.
This Report and over 66,905+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers